N/A
N=38
Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance
Impaired Glucose Tolerance
Bottom Line
View on ClinicalTrials.gov: NCT01375959 ↗Enrolled (actual)
38
Serious AEs
1.3%
Results posted
Aug 2020
Primary outcome: Primary: Post Meal Glucose Area Under the Curve — 508; 513 mg*hr/dL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- resveratrol (Dietary_supplement); Placebo (Drug)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Albert Einstein College of Medicine
- Primary completion
- Apr 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Post Meal Glucose Area Under the Curve |
508; 513 | — |
| SECONDARY Insulin Sensitivity Using a Modification of the Matsuda Index |
2.3; 2.0 | — |
Summary
Resveratrol is a substance found in many plants, including grapes and red wine, which is widely used as a nutritional supplement. Studies in cells and lower animals show that resveratrol has many potential benefits, including prolonging lifespan, preventing cancer and heart disease and normalization of glucose metabolism. Although use of this agent shows great promise in the treatment and/or prevention of diabetes, there have been no studies reported to date in humans. As an initial step, this proposal is for a 6 week pilot study of resveratrol treatment in older adults with impaired glucose tolerance (IGT) in order to explore its effects on post-meal blood glucose metabolism. Preliminary studies will also be conducted to explore how resveratrol works by studying cellular function (in muscle samples obtained from study participants) and by testing resveratrol's effect on blood vessel function.
Eligibility Criteria
Inclusion Criteria
- impaired glucose tolerance
Exclusion Criteria
- history of estrogen-dependent neoplasm
- use of certain drugs: high dose statins, warfarin, antiepileptics
- current treatment with anti-diabetes medications
- impaired liver or kidney function
Data sourced from ClinicalTrials.gov (NCT01375959). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.